

DR. HOWARD MUNTZ

Publications

Peer Reviewed Publications

1. **Muntz HG**, Matsuoka N, Jackson RL. Phospholipase activity of bovine milk lipoprotein lipase on phospholipid vesicles: influence of apolipoproteins C-II and C-III. *Biochem Biophys Res Commun* 1979;90:15-21.
2. Jackson RL, Taskinen MR, Matsuoka N, Fitzharris TJ, Harmony JAK, **Muntz HG**, Neely EK, Cardin AD, Johnson JD. Lipoprotein structure and the mechanism of action of lipoprotein lipase. In: *Atherosclerosis V: Proceedings of the Fifth International Symposium*. New York: Raven Press 1980:180-3.
3. Shirai K, Fitzharris TJ, Shinomiya M, **Muntz HG**, Harmond JAK, Jackson RL, Quinn, DM. Lipoprotein lipase catalyzed hydrolysis of phosphatidylcholine of guinea pig very low density lipoproteins and discoidal complexes of phospholipid and apolipoprotein; effect of apolipoprotein C-II on the catalytic mechanism. *J Lipid Res* 1983;24:721-30.
4. **Muntz HG**, Falkenberry S, Fuller AF Jr. Fallopian tube prolapse after hysterectomy. *J Reprod Med* 1988;33:467-9.
5. **Muntz HG**, Rutgers JL, Tarraza HM, Fuller AF Jr. Carcinosarcomas and mixed mullerian tumors of the fallopian tube. *Gynecol Oncol* 1989;4:109-15.
6. **Muntz HG**, Tarraza HM, Granai CO, Fuller AF Jr. Primary adenocarcinoma of the fallopian tube. *Eur J Gynæcol Oncol* 1989;10:239-49.
7. Goff BA, Muntz HG. Herpes simplex infection in pregnancy. *Clin Adv Treat Infect* 1990;4:4-5.
8. Goff BA, **Muntz HG**. Gunshot wounds to the gravid uterus: case report and literature review. *J Reprod Med* 1990;35:436-8.

9. **Muntz HG**, Goff BA, Fuller FA Jr. Recurrent ovarian granulosa cell tumor: role of combination chemotherapy with report of a long-term response to a cyclophosphamide, doxorubicin, and cisplatin regimen. *Eur J Gynaecol Oncol* 1990;11:263-8.
10. **Muntz HG**, Tarraza HM, Goff BA, Granai CO, Rice LW, Nikrui N, Fuller AF Jr. Combination chemotherapy in advanced adenocarcinoma of the fallopian tube. *Gynecol Oncol* 1991;40:268-73.
11. Tarraza HM, **Muntz HG**, Cain DE, Granai CO, Fuller AF Jr. Patterns of recurrence of primary carcinoma of the vagina. *Eur J Gynaecol Oncol* 1991;12:89-92.
12. Toub DB, Goff BA, **Muntz HG**. Tuberculosis endometritis presenting as postmenopausal bleeding. *J Reprod Med* 1991;36:616-8.
13. **Muntz HG**, Ferry JA, Flynn D, Fuller AF Jr, Tarraza HM. Stage IE primary malignant lymphoma of the uterine cervix. *Cancer* 1991;68:2023-2032.
14. **Muntz HG**, Goff BA, Thor AD, Tarraza HM. Posthysterectomy carcinoma of the fallopian tube mimicking a vesicovaginal fistula. *Obstet Gynecol* 1992;79:853-856.
15. Goff BA, Atanasoff P, Brown E, **Muntz HG**, Bell DA, Rice LW. Endocervical glandular atypia in Papanicolaou smears. *Obstet Gynecol* 1992;79:101-4.
16. **Muntz HG**, Brown E. Refractory lactic acidosis and hypoglycemia complicating advanced gynecologic malignancy. *Intl J Gynecol Oncol* 1992;2:163-167.
17. Pressley RH, **Muntz HG**, Falkenberry S, Rice LW. Serum lactic dehydrogenase as a tumor marker in dysgerminoma. *Gynecol Oncol* 1992;44:281-283.
18. Gustafson ML, Lee MM, Scully RE, Moncure AC, Hirakawa T, Goodman AK, **Muntz HG**, Donahoe PK, MacLaughlin DT, and Fuller AF Jr. Mullerian inhibiting substance as a marker for ovarian sex-cord tumor. *N Engl J Med* 1992;326:466-471.
19. **Muntz HG**, Bell DA, Lage JM, Goff BA, Feldman S, Rice LW. Adenocarcinoma in-situ of the uterine cervix. *Obstet Gynecol* 1992;80:935-939.

20. Goff BA, **Muntz HG**, Bell DA, Wertheim I, Rice LW. Human Papillomavirus typing in patients with Papanicolaou smears showing squamous atypia. *Gynecol Oncol* 1993;48:384-388.
21. Tarraza HM, **Muntz HG**, DeCain M, Jones MA. Cervical metastases in advanced ovarian malignancies. *Eur J Gynæcol Oncol* 1993;14:274-278.
22. Goff BA, Mueller PR, **Muntz HG**, Rice LW. Small chest-tube drainage followed by bleomycin sclerosis for malignant pleural effusions. *Obstet Gynecol* 1993;81:993-996.
23. Tepler I, Cannistra SA, Frei E, III, Gonin R, Anderson KC, Demetri G, Niloff J, Goodman H, **Muntz H**, Muto M, Sheets E, Elias AD, Mazanet R, Wheeler C, Ayash L, Schwartz G, McCauley M, Gaynes L, Harvey S, Schnipper LE, Antman KH. Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy. *J Clin Oncol* 1993;11:1583-1591.
24. Goff BA, Rice LW, Fleischhacker D, **Muntz HG**, Falkenberry SS, Nikrui N, Fuller AF Jr. Uterine leiomyosarcoma and endometrial stromal sarcoma: Lymph node metastases and sites of recurrence. *Gynecol Oncol* 1993;50:105-109.
25. Jacoby A, Thor A, Fuller AF Jr, **Muntz HG**. Leiomyosarcoma of the fallopian tube. *Gynecol Oncol* 1993;51:404-407.
26. Goff BA, Rice LW, Fleischhacker DS, Abujawadeh GM, **Muntz HG**. Large loop excision of the transformation zone in patients with exocervical squamous intraepithelial lesions. *Eur J Gynæcol Oncol* 1994;15:275-262.
27. Goff BA, Rice LW, **Muntz HG**, Nikrui N, Fuller AF, Jr. Surgical stage IV endometrial carcinoma. *Gynecol Oncol* 1994;52:237-240.
28. Goff BA, Kato D, Schmidt RA, Ek M, **Muntz HG**, Cain JM, Tamimi HK, Figge DC, Greer BE. Uterine papillary serous carcinoma: Patterns of metastatic spread. *Gynecol Oncol* 1994;54:264-268.
29. **Muntz HG**, Jones MA, Goff BA, Rice LW, Nikrui N, Fuller AF, Jr., Tarraza HM. Malignant mixed Mullerian tumors (MMMT) of the ovary: experience with surgical cytoreduction and combination chemotherapy. *Cancer* 1995;76:1209-1213.

30. Swisher EM, Gown AM, Skelly M, Ek M, Tamimi HK, Cain JM, Greer BE, **Muntz HG**, Goff BA. Expression of epidermal growth factor receptor, p53, her-2/neu, and KI-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcomas. *Gynecol Oncol* 1996;60:81-88.
31. Goff BA, Sainz de le Cuesta R, **Muntz HG**, Fleischhacker D, Ek M, Rice LW, Nikrui N, Tamimi HK, Cain JM, Greer BE, Fuller AF, Jr. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. *Gynecologic Oncology* 1996;60:412-417.
32. Goff BA, Shy K, Greer BE, **Muntz HG**, Skelly M, Gown AM. Overexpression and relationships of HER-2/neu, epidermal growth factor receptor, p53, Ki-67, and tumor necrosis factor alpha in epithelial ovarian. *Eur J Gynæcol Oncol* 1996;17:487-492.
33. **Muntz HG**. Can cervical adenocarcinoma in situ be safely managed by conization alone? (Editorial) *Gynecol Oncol* 1996;61:301-303.
34. Goff BA, **Muntz HG**, Cain JM. Is Adam worth more than Eve? The financial impact of gender bias in the federal reimbursement of gynecologic procedures. *Gynecol Oncol* 1997;64:372-377.
35. Goff BA, **Muntz HG**, Cain JM. Comparison of 1997 Medicare relative value units for gender-specific procedures: Is Adam still worth more than Eve? *Gynecol Oncol* 1997;66:313-319.
36. Grice J, Marit E, Greer B, Koh WJ, **Muntz HG**, Cain JM, Tamimi H, Stelzer K, Figge D, Goff BA. Uterine papillary serous carcinoma: Evaluation of long-term survival in surgically staged patients. *Gynecol Oncol* 1998;69:69-73.
37. Goff BA, **Muntz HG**, Greer BE, Tamimi HK, Gown A. Oncogene expression: Long-term compared with short-term survival in patients with advanced epithelial ovarian cancer. *Obstet Gynecol* 1998;92:88-93.
38. Cohn DE, Peters WA 3rd, **Muntz HG**, Wu R, Greer BE, Tamimi HK, Drescher CW, Smith MR, Yon JL, Schmidt R, Goff BA. Adenocarcinoma of the uterine cervix metastatic to lymph nodes. *Am J Obstet Gynecol* 1998;178:1131-7.

39. **Muntz HG**, Goff BA, Madsen BL, Yon JL. Port-site recurrence after laparoscopic surgery for endometrial cancer. *Obstet Gynecol* 1999;93:807-809.
40. Goff BA, **Muntz HG**, Paley PJ, Tamimi HK, Koh W-J, Greer BE. Impact of surgical staging in women with locally advanced cervical cancer. *Gynecol Oncol* 1999;74:436-442.
41. **Muntz HG**. "Curbside" consultations in gynecologic oncology: A closer look at a common practice. *Gynecol Oncol* 1999;74:456-459.
42. Goff BA, Mandel LS, **Muntz HG**, Melancom CH. Ovarian cancer diagnosis: Results of a national ovarian cancer survey. *Cancer* 2000;89:2068-2075.
43. Goff BA, Sallin J, Garcia R, VanBlaricom A, Paley PJ, **Muntz HG**. Evaluation of p27 in preinvasive and invasive malignancies of the cervix. *Gynecol Oncol* 2003;88:40-44.
44. **Muntz HG**, Goff BA, McGonigle K, Isacson C. The significance of psammoma bodies in screening cervical cytology smears. *Am J Obstet Gynecol*. 2003;188:1609-1614.
45. **Muntz HG**. Understanding the Natural History of Ovarian Cancer, and the Role of Modern Surgical Management. *Virginia Mason Bulletin*, Summer 2004;58:22-27.
46. Goff BA, Mandel LS, Melancon CH, **Muntz HG**. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. *JAMA* 2004;291:2705-2712.
47. Muntz HG. Ovarian cancer: Recent advances in combination chemotherapy. *Virginia Mason Bulletin*, Spring 2005;59:25-32.
48. Begley JS, Kupferman SP, Kuznetsov DD, Kobashi KC, Govier FE, McGonigle KF, Muntz HG. Incidence and management of abdominal sacrocolpopexy mesh erosions. *Am J Obstet Gynecol* 2005;192:1956-1962.
49. Goff BA, Muntz HG. Ovarian Cancer Screening. *Women's Health in Primary Care* 2005;9:262-268.

50. Govier FE, Kobashi KC, Kozlowski PM, Kuznetsov DD, Begley SJ, McGonigle KF, Muntz HG. High complication rate identified in sacrocolpopexy patients attributed to silicone mesh. *Urology* 2005;65:1099-1103.
51. Muntz HG, McGonigle KD, Malpass TW, Robertson MD, Kamarauskiene D, Weiden P. Phase II study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal cancer. *Cancer Investigation* 2006; 24; 39-41.
52. Goff BA, Matthews BJ, Wynn M, Muntz HG, Lishner DM, Baldwin L-M. Ovarian cancer: Patterns of surgical care across the United States. *Gynecologic Oncology* 2006;103:383-390.

TEXTBOOK CHAPTERS:

1. Muntz HG. Cervical cancer screening and management of the abnormal Papanicolaou smear. In: *Primary Care of Women*. Lemcke DP, Pattison J, Marshall LA, Cowley DS (eds). Appleton & Lange, Norwalk, CT, 1995, pp 467-476.
2. Muntz HG. Fallopian tube. In: *Atlas of Clinical Gynecology*. Goff BA (ed). Current Medicine, Philadelphia, PA, 1998, pp 7.1-7.13.
3. Muntz HG. Cervical cancer screening and management of the abnormal Papanicolaou smear. In: *Current Care of Women: Diagnosis & Treatment*. 2nd Edition. Lemcke DP, Pattison J, Marshall LA, Cowley DS (eds). McGraw-Hill/Appleton & Lange, New York, NY, 2004, pp. 520-531.

SELECTED ABSTRACTS: (Presented at National Meetings)

1. Muntz HG, Lage J, Bell DA, Goff BA, Feldman S, Rice LW. Adenocarcinoma-in-situ of the uterine cervix. *Proceedings of the Society of Gynecologic Oncologists, 23rd Annual Meeting, San Antonio, TX, March, 1992.*
2. Goff BA, Muntz HG, Cain JM. Is Adam worth more than Eve? The financial impact of gender bias in the federal reimbursement of gynecologic procedures. *Proceedings of the Society of Gynecologic Oncologists, 28th Annual Meeting, March 1997.*

3. Muntz HG. "Curbside" consultations in gynecologic oncology: A closer look at a common practice. Proceedings of the Society of Gynecologic Oncologists, 30th Annual Meeting, San Francisco, CA, March 1999.
4. Goff BA, Muntz HG, Paley PJ, Tamimi HK, Koh W-J, Greer BE. Impact of surgical staging in women with locally advanced cervical cancer. Proceedings of the Society of Gynecologic Oncologists, 30th Annual Meeting, San Francisco, CA, March 1999.
5. Goff BA, Mandel LS, Muntz HG, Melancon CH. Ovarian cancer diagnosis: Results of a national ovarian cancer survey. Proceedings of the Society of Gynecologic Oncologists, 31st Annual Meeting, San Diego, CA, February 2000.
6. Goff BA, Salin J, Rochelle GL, Vanblaricom A, Paley PJ, Muntz HG. Evaluation of p27 expression in preinvasive and invasive malignancies of the cervix. Proceedings of the Society of Gynecologic Oncologists, 33rd Annual Meeting, Miami, FL, March 16-20, 2002.
7. Alberts D, Wolf J, Muntz H, Hatch K, Carrier A, Eggert S, Heald A. A phase I, dose-escalation trial of E1A gene transfer with chemotherapy for treatment of advanced ovarian cancer. Proc Am Soc Clin Oncol 2002;21:abstract 69.
8. Goff B, Mandel L, Muntz H, Melancon CH. Symptoms of ovarian cancer: how often are they found in women presenting to primary care clinics? Society of Gynecologic Oncologists, 34th Annual Meeting, New Orleans, LA, January 31–February 4, 2003. Gynecol Oncol 2003;88:237-238.
9. Goff BA, Mandel LS, Melancon CH, Muntz HG. Ovarian cancer symptoms: a randomized trial. Proceedings of the Society of Gynecologic Oncologists, 35th Annual Meeting, San Diego, CA, February 7-11, 2004.
10. Kuznetsov D, Govier F, Kobashi K, Kozlowski P, Begley S, McGonigle K, Muntz H. A high vaginal erosion rate identified in sacrocolpopexy patients using silicone mesh. Proceedings of the Society for Urodynamics & Female Urology (SUFU), Scottsdale, AZ, Feb 26-29, 2004.
11. Robertson M, Malpass T, McGonigle K, Weiden P, Muntz H. Phase II study of intraperitoneal topotecan as consolidation therapy in ovarian cancer. Proceedings of the

American Society of Clinical Oncology 40th Annual Meeting, New Orleans, LA, June 5-8, 2004.

12. Muntz HG, McGonigle KD, Malpass TW, Robertson MD, Kamarauskiene D, Weiden P. Phase II study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal cancer. Society of Gynecologic Oncologists' 36th Annual Meeting, Miami, FL, Feb. 7-11, 2005: abstract 199.
13. Goff B, Larson E, Mathews B, Andrilla H, Lishner D, Baldwin LM, Lackey M, Muntz H. What factors predict comprehensive surgical treatment of ovarian cancer patients? *Gynecol Oncol* 2006; 101:S2: abstract 1.
14. Malpass TW, McGonigle K, Robertson M, Weiden P, Muntz HG. Mature results of a Phase II study of intraperitoneal topotecan as consolidation therapy in ovarian cancer. Proceedings of the American Society of Clinical Oncology 43rd Annual Meeting, Chicago, IL, June 1-5, 2007: Abstract 5570.